Syndax Pharmaceuticals Inc. (SNDX) and Liquidia Technologies Inc. (NASDAQ:LQDA) Comparison side by side

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) and Liquidia Technologies Inc. (NASDAQ:LQDA), both competing one another are Biotechnology companies. We will contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Syndax Pharmaceuticals Inc. 8 156.70 N/A -2.66 0.00
Liquidia Technologies Inc. 9 8.71 N/A -2.51 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Syndax Pharmaceuticals Inc. and Liquidia Technologies Inc.


Table 2 shows us Syndax Pharmaceuticals Inc. and Liquidia Technologies Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Syndax Pharmaceuticals Inc. 0.00% -107.5% -71.5%
Liquidia Technologies Inc. 0.00% -222.5% -78.3%


The Current Ratio and a Quick Ratio of Syndax Pharmaceuticals Inc. are 6.2 and 6.2. Competitively, Liquidia Technologies Inc. has 5.6 and 5.6 for Current and Quick Ratio. Syndax Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Liquidia Technologies Inc.

Insider & Institutional Ownership

Institutional investors owned 72.4% of Syndax Pharmaceuticals Inc. shares and 61.4% of Liquidia Technologies Inc. shares. Insiders owned roughly 0.1% of Syndax Pharmaceuticals Inc.’s shares. On the other hand, insiders owned about 1.1% of Liquidia Technologies Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Syndax Pharmaceuticals Inc. 4.23% 6.31% 32.96% 75.82% 45.68% 115.73%
Liquidia Technologies Inc. -1.88% -8.17% -24.48% -47.03% -33.55% -66.25%

For the past year Syndax Pharmaceuticals Inc. had bullish trend while Liquidia Technologies Inc. had bearish trend.


Syndax Pharmaceuticals Inc. beats Liquidia Technologies Inc. on 5 of the 7 factors.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, and Merck KGaA and Pfizer; collaborative research and development agreement with National Cancer Institute; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.